% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • sudnwealth sudnwealth Jun 13, 2014 9:17 PM Flag

    FOTD (OT)

    I hope you grabbed some ACRX--the analysts were out in force this week promoting it. PDUFA in 6 weeks and approval chances are 90% according to more than one analyst. Lets talk on July 27th. :))

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ACRX - absolutely no chance of approval. Groggy post op patients self administering little blue tabs under their tongues, which are more than likely to finish up on the floor. Quite ridiculous idea. Straight red from the FDA

    • afriendofthedevilsafriendofmine afriendofthedevilsafriendofmine Jun 14, 2014 12:30 PM Flag

      You may be right as you have often been in the past. Because it isn't my style doesn't mean it won't do well.
      Good luck with it.

      • 2 Replies to afriendofthedevilsafriendofmine
      • FOTD --
        Check this out....last post on this board;
        dirtystockbird • Jun 13, 2014 10:17 AM
        7users liked this postsusers disliked this posts0Reply
        Piper approval expected
        Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $14 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) saying following travel with management they are looking for a timely Zalviso approval. Amsellem commented, "We spent the past couple of days traveling with AcelRx senior management in meetings with investors. We came away with additional color on ACRX s commercial launch plans for Zalviso, its patient-controlled analgesia (PCA) system for post-operative pain that incorporates its sublingual form of sufentanil (known as the NanoTab). We continue to believe that the extensive body of efficacy and safety data on Zalviso points to a timely approval around the FDA action date of 7/27/14 (and the fact that this is a 505(b)(2) filing doesn t hurt). With peak U.S. sales potential of at least $300M-$400M in our view (along with a long asset duration as a drug-device combo with an extensive patent estate), plus potential royalties from partner Grunenthal in Europe, ACRX remains attractively valued at a market cap of under $400M." For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here. Shares of AcelRx Pharmaceuticals closed at $9.16 yesterday. Less

      • accurate

12.09-0.31(-2.50%)Sep 23 4:00 PMEDT